Effect of Carbetocin in Prevention of PPH

Background: Oxytocin is the main uterotonic drug for avoiding post-partum hemorrhage (PPH), which is a major cause of morbidity for mothers. Clinical studies have shown that carbetocin can reduce PPH risk without increasing the risk of major side effects. The purpose of current investigation was to evaluate carbetocin’s potential for PPH prophylaxis. Methods: In this observational analysis, 100 women who had blood loss and major PPH incidents during vaginal (n=50) and cesarean (n=50) deliveries were included. Of these, half had carbetocin at tertiary care facility over the course of study period, which lasted for 2 years from January 2022to December 2023. With SPSS version 25.0, the blood loss was approximated, and the findings were examined. Results: Between the groups having vaginal and cesarean deliveries, the mean age (~31 years), mean body mass index (~27kg/m2), and mean parity (~1.4) were comparable between those who received prophylactic carbetocin and those who did not. The intrapartum blood loss during vaginal birth was 227.28±157.32ml and 249.17±179.35ml, respectively; p=0.0873 for women treated with and without carbetocin. During CS, women who received carbetocin prophylaxis had significantly less mean± SD blood loss [651.47±321.58ml] than those who did not [831.38±361.96ml; p=0.0001]. Overall, total blood loss was considerably lower in women getting carbetocin prophylaxis than in those not (p<0.001). Conclusion: The preventive use of carbetocin significantly decreased blood loss during caesarean sections in cases of PPH when compared to vaginal deliveries.